ICU Medical, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Unaudited results; comparisons are with the corresponding 2022 periods. ICU Medical develops and sells infusion systems and consumables, vascular access, and critical-care products. The 2022 Smiths Medical acquisition materially expanded its product portfolio and debt burden.
Financial results
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $549.3M | $561.0M | $1,118.0M | $1,104.1M |
| Gross profit / margin | $192.3M / 35.0% | $167.6M / 29.9% | $384.4M / 34.4% | $336.4M / 30.5% |
| Operating income (loss) | $2.8M | $(0.05)M | $12.2M | $(42.2)M |
| Net loss | $(9.9)M | $(7.5)M | $(19.7)M | $(45.5)M |
| Net loss per diluted share | $(0.41) | $(0.31) | $(0.82) | $(1.91) |
| Operating cash flow | Not separately presented for the quarter | $39.8M | $(62.7)M |
Revenue by business unit, Q2: Consumables $237.0M, down 1.7%; Infusion Systems $153.1M, up 3.1%; Vital Care $159.2M, down 7.1%. For the first half, revenue rose 1.3% year over year, while constant-currency revenue was approximately flat. The six-month comparison includes eight additional Smiths Medical billing days in 2023.
Cash, debt and liquidity: Cash and cash equivalents were $195.9M and short-term investments $1.8M at June 30, versus combined cash and investments of $213.0M at year-end 2022. Debt carrying value was $1.641B, with $40.4M current; principal outstanding was approximately $1.663B. The $500M revolving facility was undrawn. The company reported covenant compliance and believes liquidity sources are sufficient for the next 12 months.
First-half capital spending was $32.5M; management estimated 2023 capital expenditures of $80M–$100M. Operating cash flow included a $46.8M reduction in accounts receivable, partly reflecting the receivables purchase program, and a $76.0M inventory cash use as the company built safety stock.
Material changes and management commentary
- Gross margin improved substantially, which management attributed mainly to the absence of 2022 inventory purchase-accounting charges and lower freight costs; foreign exchange partly offset the improvement.
- Q2 revenue declined 2.1%, despite Infusion Systems growth, as lower Vital Care and Consumables sales weighed on results. Management cited weaker IV-solution and vascular-access sales, partly offset by growth in certain infusion, temperature-management and other products.
- Net interest expense increased to $24.1M in Q2 from $15.4M, primarily due to higher SOFR rates, partly offset by interest-rate swaps. First-half net interest expense was $46.6M versus $28.5M.
- Restructuring, transaction and integration costs were $12.4M in Q2 and $23.4M for the first half, primarily related in 2023 to Smiths Medical integration. The company expects to pay most unpaid restructuring costs during the remainder of 2023 and 2024.
- The company recorded a $4.0M Q2 expense from changes in contingent earn-out fair value, compared with a $27.2M gain in Q2 2022; this comparison materially affected operating results.
Outlook, risks and contingencies
- Management provided a 2023 capital expenditure estimate of $80M–$100M, but no specific revenue or earnings guidance is stated in the supplied filing text.
- Key risks include supplier concentration and supply-chain disruption, inflation and freight volatility, foreign-exchange movements, higher interest rates, changes in product demand and healthcare cost pressures. Medline represented approximately 15% of revenue in both comparison periods.
- Smiths Medical’s 2021 FDA Warning Letter concerned medical-device reporting and quality-system issues at its Oakdale facility. The estimated field-service corrective-action liability was $47.4M at June 30, 2023; actual costs depend on the work required to achieve regulatory clearance.
- In July 2023, a tornado damaged the warehouse and stored inventory at Pfizer’s Rocky Mount facility, which manufactures certain sterile injectable products for ICU Medical. Products made there generated approximately $7.2M of revenue in the first half of 2023 and $37.6M in 2022; the filing does not quantify the event’s expected financial impact.
- The company sold $290.3M of receivables under a new uncommitted purchase program in the first half, receiving $288.6M and recording a $1.7M loss. It reported no material changes to previously disclosed risk factors and stated that disclosure controls were effective.
Important facts for investors to verify
- Whether improved gross margins persist after the 2022 purchase-accounting and freight-cost benefits, and whether revenue stabilizes across the three business units.
- Debt-service capacity, exposure to variable rates, and covenant headroom; assess the effect of the new $300M interest-rate swap alongside the existing hedges.
- Progress, cost and regulatory status of the Smiths Medical Oakdale corrective action, and whether the recorded $47.4M provision remains adequate.
- The operational and financial impact of the Pfizer facility tornado, including supply continuity for affected products.
- Inventory levels, cash conversion and continued use and cost of receivables sales; first-half operating cash flow benefited from receivables reduction while inventory increased.
- One-time tax benefits and contingent earn-out revaluations when assessing the underlying trend in losses and operating performance.